The Safe Use of (125)I-Seeds as a Localization Technique in Breast Cancer during Pregnancy

SIMPLE SUMMARY: The results of this multidisciplinary study can function as a clinician’s guide for determining the preferred surgical localization technique for breast-conserving surgery in pregnant women with breast cancer and its timing, without avoiding the use of a (125)I-seed. The maximum expo...

Descripción completa

Detalles Bibliográficos
Autores principales: Heeling, Eva, van de Kamer, Jeroen B., Methorst, Michelle, Bruining, Annemarie, van de Meent, Mette, Vrancken Peeters, Marie-Jeanne T. F. D., Lok, Christianne A. R., van der Ploeg, Iris M. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296371/
https://www.ncbi.nlm.nih.gov/pubmed/37370839
http://dx.doi.org/10.3390/cancers15123229
Descripción
Sumario:SIMPLE SUMMARY: The results of this multidisciplinary study can function as a clinician’s guide for determining the preferred surgical localization technique for breast-conserving surgery in pregnant women with breast cancer and its timing, without avoiding the use of a (125)I-seed. The maximum exposure to the fetus remains well below 100 millisieverts (mSv), the threshold value for tissue damage caused by radiation. If the exposure should remain below 1 mSv, the implantation and surgical removal of the (125)I-seed should occur within two weeks after a GA of 26 weeks, and within one week after a GA of 32 weeks. The contribution of an axillary seed is negligible (at maximum, 2.3% of the seed implanted in the breast). ABSTRACT: Introduction: Some aspects of the treatment protocol for breast cancer during pregnancy (PrBC) have not been thoroughly studied. This study provides clarity regarding the safety of the use of (125)I-seeds as a localization technique for breast-conserving surgery in patients with PrBC. Methods: To calculate the exposure to the fetus of one (125)I-seed implanted in a breast tumor, we developed a model accounting for the decaying (125)I-source, time to surgery, and the declining distance between the (125)I-seed and the fetus. The primary outcome was the maximum cumulative fetal dose of radiation at consecutive gestational ages (GA). Results: The cumulative fetal dose remains below 1 mSv if a single (125)I-seed is implanted at a GA of 26 weeks. After a GA of 26 weeks, the fetal dose can be at a maximum of 11.6 mSv. If surgery takes place within two weeks of implantation from a GA of 26 weeks, and one week above a GA of 32 weeks, the dose remains below 1 mSv. Conclusion: The use of (125)I-seeds is safe in PrBC. The maximum fetal exposure remains well below the threshold of 100 mSv, and therefore, does not lead to an increased risk of fetal tissue damage. Still, we propose keeping the fetal dose as low as possible, preferably below 1 mSv.

Ejemplares similares